8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Feb 4, 2026·SEC
Material company update
Oct 21, 2025·SEC
Lipella Pharmaceuticals Inc.(LIPO)Earnings, Financials & Key Ratios
LIPO•NASDAQ
Price updated Jun 19, 2026
AboutLipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.Show more
- Revenue$536K+19.3%
- EBITDA-$5M-7.0%
- Net Income-$5M-8.6%
- EPS (Diluted)-4.79+22.2%
- Gross Margin-573.65%+0.4%
- EBITDA Margin-946.69%+10.3%
- Operating Margin-947.23%+10.3%
- Net Margin-935.25%+9.0%
- ROE-198.12%-67.7%
LIPO Key Insights
Lipella Pharmaceuticals Inc. (LIPO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 95 (top 5%)
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Profits declining 140.9% over 5 years
- ✗Negative free cash flow
- ✗Sales declining 5.0% over 5 years
- ✗Shares diluted 39.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LIPO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LIPO Price & Volume
Lipella Pharmaceuticals Inc. (LIPO) stock price & volume — 10-year historical chart
Loading chart...
LIPO Growth Metrics
Lipella Pharmaceuticals Inc. (LIPO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-5.04%
3 Years27.41%
TTM-61.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-25.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM41.31%
Return on Capital
10 Years-114.59%
5 Years-114.59%
3 Years-132.79%
Last Year-198.8%
LIPO Peer Comparison
Lipella Pharmaceuticals Inc. (LIPO) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 PHAT | 864.2M | 10.88 | -3.59 | 216.93% | -61.95% |
Compare LIPO vs Peers
Lipella Pharmaceuticals Inc. (LIPO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LIPO Income Statement
Lipella Pharmaceuticals Inc. (LIPO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 694.75K | 961.68K | 259.35K | 184.16K | 449.62K | 536.36K | 173.67K |
Revenue Growth % | - | 38.42% | -73.03% | -28.99% | 144.15% | 19.29% | -61.37% |
Cost of Goods Sold | 682.89K | 975.96K | 1.46M | 2.55M | 3.04M | 3.61M | 3.57M |
COGS % of Revenue | 98.29% | 101.48% | 561.71% | 1383.43% | 675.87% | 673.65% | - |
Gross Profit | 11.86K▲ 0% | -14.28K▼ 220.4% | -1.2M▼ 8287.2% | -2.36M▼ 97.4% | -2.59M▼ 9.5% | -3.08M▼ 18.8% | -3.39M▲ 0% |
Gross Margin % | 1.71% | -1.48% | -461.71% | -1283.43% | -575.87% | -573.65% | -1954.73% |
Gross Profit Growth % | - | -220.41% | -8287.22% | -97.38% | -9.55% | -18.83% | - |
Operating Expenses | 65.65K | 42.59K | 718.38K | 226.19K | 2.16M | 2M | 2.02M |
OpEx % of Revenue | 9.45% | 4.43% | 277% | 122.83% | 479.68% | 373.58% | - |
Selling, General & Admin | 65.65K | 42.59K | 718.38K | 226.19K | 2.16M | 2M | 2.23M |
SG&A % of Revenue | 9.45% | 4.43% | 277% | 122.83% | 479.68% | 373.58% | - |
Research & Development | 682.89K | 975.96K | 1.46M | 2.55M | 0 | 0 | 0 |
R&D % of Revenue | 98.29% | 101.48% | 561.71% | 1383.43% | - | - | - |
Other Operating Expenses | -682.89K | -975.96K | -1.46M | -2.55M | 0 | 0 | -216.12K |
Operating Income | -53.79K▲ 0% | -56.86K▼ 5.7% | -1.92M▼ 3269.3% | -2.59M▼ 35.2% | -4.75M▼ 83.3% | -5.08M▼ 7.0% | -5.41M▲ 0% |
Operating Margin % | -7.74% | -5.91% | -738.71% | -1406.26% | -1055.55% | -947.23% | -3115.15% |
Operating Income Growth % | - | -5.71% | -3269.26% | -35.17% | -83.26% | -7.05% | - |
EBITDA | 0 | -53.69K | -1.86M | -2.59M | -4.74M | -5.08M | -5.41M |
EBITDA Margin % | - | -5.58% | -716.66% | -1405.37% | -1055.18% | -946.69% | -3113.49% |
EBITDA Growth % | - | - | -3361.73% | -39.25% | -83.31% | -7.03% | -24.13% |
D&A (Non-Cash Add-back) | 53.79K | 0 | 0 | 0 | 1.69K | 2.89K | 2.89K |
EBIT | -53.79K | -53.69K | -1.86M | -2.59M | -4.61M | -5.02M | -5.33M |
Net Interest Income | -8.06K | -4.79K | -6.73K | -7.93K | 126.99K | 64.28K | 80.2K |
Interest Income | 334 | 3.17K | 104 | 1.68K | 137.84K | 64.28K | 80.2K |
Interest Expense | 8.39K | 7.96K | 6.83K | 9.61K | 10.85K | 0 | 0 |
Other Income/Expense | -8.06K | -4.79K | 50.35K | -7.98K | 126.99K | 64.28K | 80.2K |
Pretax Income | -61.85K▲ 0% | -61.66K▲ 0.3% | -1.87M▼ 2925.6% | -2.6M▼ 39.3% | -4.62M▼ 77.8% | -5.02M▼ 8.6% | -5.33M▲ 0% |
Pretax Margin % | -8.9% | -6.41% | -719.3% | -1410.59% | -1027.31% | -935.25% | -3068.97% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -61.85K▲ 0% | -61.66K▲ 0.3% | -1.87M▼ 2925.6% | -2.6M▼ 39.3% | -4.62M▼ 77.8% | -5.02M▼ 8.6% | -5.33M▲ 0% |
Net Margin % | -8.9% | -6.41% | -719.3% | -1410.59% | -1027.31% | -935.25% | -3068.97% |
Net Income Growth % | - | 0.31% | -2925.61% | -39.25% | -77.81% | -8.6% | -25.01% |
Net Income (Continuing) | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M | -5.33M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.24▲ 0% | -0.23▲ 4.2% | -4.38▼ 1804.3% | -5.12▼ 16.9% | -6.16▼ 20.3% | -4.79▲ 22.2% | -1.17▲ 0% |
EPS Growth % | - | 4.17% | -1804.35% | -16.89% | -20.31% | 22.24% | 41.31% |
EPS (Basic) | -0.24 | -0.23 | -4.00 | -5.12 | -6.16 | -4.79 | - |
Diluted Shares Outstanding | 260K | 266.4K | 426.01K | 507.58K | 750.38K | 1.05M | 4.55M |
Basic Shares Outstanding | 260K | 266.4K | 466.48K | 507.36K | 749.83K | 1.05M | 4.55M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
LIPO Balance Sheet
Lipella Pharmaceuticals Inc. (LIPO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 118.92K | 699.43K | 1.81M | 5.8M | 3.43M | 2.62M | 2.08M |
Cash & Short-Term Investments | 26K | 606.74K | 1.71M | 5.12M | 3.29M | 2.18M | 1.86M |
Cash Only | 26K | 606.74K | 1.41M | 5.12M | 3.29M | 2.18M | 1.86M |
Short-Term Investments | 0 | 0 | 300.55K | 0 | 0 | 0 | 0 |
Accounts Receivable | 83.89K | 69.03K | 0 | 113.66K | 32.29K | 84.71K | 0 |
Days Sales Outstanding | 44.07 | 26.2 | - | 225.27 | 26.21 | 57.65 | 111.56 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 0 | 255.59K | 204.8K | 150.82K | 147.89K | 56.62K | 270.52K |
Property, Plant & Equipment | 0 | 255.59K | 204.8K | 150.82K | 147.89K | 56.62K | 270.52K |
Fixed Asset Turnover | - | 3.76x | 1.27x | 1.22x | 3.04x | 9.47x | 1.08x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 118.92K▲ 0% | 955.02K▲ 703.1% | 2.01M▲ 110.8% | 5.95M▲ 195.6% | 3.58M▼ 39.9% | 2.67M▼ 25.3% | 2.35M▲ 0% |
Asset Turnover | 5.84x | 1.01x | 0.13x | 0.03x | 0.13x | 0.20x | 0.05x |
Asset Growth % | - | 703.1% | 110.77% | 195.6% | -39.88% | -25.25% | 108.65% |
Total Current Liabilities | 165.67K | 207.77K | 340.63K | 1.18M | 385.36K | 754.42K | 642.4K |
Accounts Payable | 49.34K | 24.54K | 46.9K | 384.36K | 138.02K | 388.19K | 462.89K |
Days Payables Outstanding | 26.37 | 9.18 | 11.75 | 55.07 | 16.58 | 39.21 | 47.34 |
Short-Term Debt | 50K | 82.04K | 25K | 275K | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 40.04K | 0 | 0 | 0 | 0 | 0 | 0 |
Current Ratio | 0.72x | 3.37x | 5.31x | 4.92x | 8.90x | 3.47x | 3.24x |
Quick Ratio | 0.72x | 3.37x | 5.31x | 4.92x | 8.90x | 3.47x | 3.24x |
Cash Conversion Cycle | - | - | - | - | - | - | 64.22 |
Total Non-Current Liabilities | 71.59K | 283.94K | 248.71K | 96.26K | 47.37K | 0 | 219.82K |
Long-Term Debt | 50K | 50K | 50K | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 207.96K | 168.36K | 96.26K | 47.37K | 0 | 451.45K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 21.59K | 25.97K | 30.35K | 0 | 0 | 0 | 0 |
Total Liabilities | 237.26K | 491.7K | 589.34K | 1.27M | 432.73K | 754.42K | 862.22K |
Total Debt | 100K | 388.91K | 282.96K | 429.52K | 136.59K | 47.6K | 264.08K |
Net Debt | 74K | -217.82K | -1.13M | -4.69M | -3.16M | -2.14M | -1.59M |
Debt / Equity | - | 0.84x | 0.20x | 0.09x | 0.04x | 0.02x | 0.18x |
Debt / EBITDA | - | - | - | - | - | - | -0.05x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.29x |
Interest Coverage | -6.41x | -6.74x | -271.97x | -269.26x | -424.79x | - | - |
Total Equity | -118.34K▲ 0% | 463.32K▲ 491.5% | 1.42M▲ 207.3% | 4.68M▲ 228.4% | 3.14M▼ 32.7% | 1.92M▼ 39.0% | 1.49M▲ 0% |
Equity Growth % | - | 491.51% | 207.25% | 228.45% | -32.75% | -38.96% | 83.19% |
Book Value per Share | -0.46 | 1.74 | 3.34 | 9.21 | 4.19 | 1.83 | 0.33 |
Total Shareholders' Equity | -118.34K | 463.32K | 1.42M | 4.68M | 3.14M | 1.92M | 1.49M |
Common Stock | 520 | 574 | 387 | 574 | 75 | 121 | 462 |
Retained Earnings | 0 | -1.24M | -3.11M | -5.7M | -10.32M | -15.34M | -19.23M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.18M | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LIPO Cash Flow Statement
Lipella Pharmaceuticals Inc. (LIPO) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -39.12K | -28.58K | -989.27K | -1.83M | -3.15M | -3.95M | -2.36B |
Operating CF Margin % | -5.63% | -2.97% | -381.45% | -994.35% | -700.63% | -736.59% | - |
Operating CF Growth % | - | 26.94% | -3361.77% | -85.1% | -72.03% | -25.41% | -361003.99% |
Net Income | -61.85K | -61.66K | -1.87M | -2.6M | -4.62M | -5.02M | -5.33M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 1.69K | 2.89K | 2.17M |
Stock-Based Compensation | 0 | 57.71K | 728.8K | 747.4K | 1.36M | 749.4K | 80.67K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 18.73K | 7.64K | -50.21K | 9.61K | 121.2K | 200K | 1.53B |
Working Capital Changes | 14.34K | -32.28K | 197.61K | 9.52K | -9.11K | 113.23K | 369.87K |
Change in Receivables | -43.78K | 14.86K | 69.03K | -113.66K | 0 | 0 | 0 |
Change in Inventory | 0 | -14.86K | 0 | 113.66K | 0 | 0 | 0 |
Change in Payables | 33.44K | -24.8K | 22.36K | 337.46K | -246.34K | 250.18K | 74.63M |
Cash from Investing | 0 | 0 | -300.55K | 300.55K | -14.43K | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | -14.43K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | 3.21% | 0% | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -300.55M | 0 | 0 | 0 |
Cash from Financing | 25K | 609.31K | 2.1M | 5.24M | 1.34M | 2.84M | 4.22B |
Debt Issued (Net) | 25K | 57.04K | 0 | 275K | -275K | 0 | 0 |
Equity Issued (Net) | 0 | 552.27K | 2.1M | 4.96M | 1.61M | 2.84M | 6.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 4.21B |
Net Change in Cash | -14.12K▲ 0% | 580.73K▲ 4213.7% | 807.09K▲ 39.0% | 3.71M▲ 359.4% | -1.83M▼ 149.3% | -1.11M▲ 39.3% | 1.85B▲ 0% |
Free Cash Flow | -39.12K▲ 0% | -28.58K▲ 26.9% | -989.27K▼ 3361.8% | -1.83M▼ 85.1% | -3.16M▼ 72.8% | -3.95M▼ 24.8% | -2.36B▲ 0% |
FCF Margin % | -5.63% | -2.97% | -381.45% | -994.35% | -703.84% | -736.59% | -1359858.31% |
FCF Growth % | - | 26.94% | -3361.77% | -85.1% | -72.82% | -24.84% | -63934.26% |
FCF per Share | -0.15 | -0.11 | -2.32 | -3.61 | -4.22 | -3.77 | -519.14 |
FCF Conversion (FCF/Net Income) | 0.63x | 0.46x | 0.53x | 0.70x | 0.68x | 0.79x | 443.10x |
Interest Paid | 0 | 0 | 0 | 0 | 11.36K | 11.91K | 7.93K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LIPO Key Ratios
Lipella Pharmaceuticals Inc. (LIPO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | -35.75% | -197.73% | -85.18% | -118.13% | -198.12% | -208.44% |
Return on Invested Capital (ROIC) | -42.4% | -533.98% | -1407.16% | - | - | 7753.4% |
Gross Margin | -1.48% | -461.71% | -1283.43% | -575.87% | -573.65% | -1954.73% |
Net Margin | -6.41% | -719.3% | -1410.59% | -1027.31% | -935.25% | -3068.97% |
Debt / Equity | 0.84x | 0.20x | 0.09x | 0.04x | 0.02x | 0.18x |
Interest Coverage | -6.74x | -271.97x | -269.26x | -424.79x | - | - |
FCF Conversion | 0.46x | 0.53x | 0.70x | 0.68x | 0.79x | 443.10x |
Revenue Growth | 38.42% | -73.03% | -28.99% | 144.15% | 19.29% | -61.37% |
Related:LIPO Dividend History·LIPO Revenue History·LIPO Price History·LIPO P/E History·LIPO Financial Ratios·LIPO Institutional Holders
LIPO SEC Filings & Documents
Lipella Pharmaceuticals Inc. (LIPO) SEC filings — annual & quarterly reports (10-K, 10-Q)
LIPO Frequently Asked Questions
Lipella Pharmaceuticals Inc. (LIPO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lipella Pharmaceuticals Inc. (LIPO) reported $0.2M in revenue for fiscal year 2024. This represents a 75% decrease from $0.7M in 2019.
Lipella Pharmaceuticals Inc. (LIPO) grew revenue by 19.3% over the past year. This is strong growth.
Lipella Pharmaceuticals Inc. (LIPO) reported a net loss of $5.3M for fiscal year 2024.
Dividend & Returns
Lipella Pharmaceuticals Inc. (LIPO) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
Lipella Pharmaceuticals Inc. (LIPO) had negative free cash flow of $2.36B in fiscal year 2024, likely due to heavy capital investments.